论文部分内容阅读
为了观察替硝唑治疗牙周炎的疗效和药物不良反应，用替硝唑Ⅲ期临床实验给药方案１．０ｇ·ｄ－１，ｑｄ。首日加倍，每疗程总量４．０ｇ治疗牙周炎，结果显示疗效明显，但药物不良反应发生率较高。本研究以分服替硝唑日剂量方案治疗牙周炎３６例（替硝唑２组），用甲硝唑治疗牙周炎３９例（甲硝唑组）与Ⅲ期临床试验的顿服日剂量方案组３８例（替硝唑１组）比较。结果显示，服药后三组患者除菌斑指数外，各牙周临床指数均明显降低（Ｐ＜０．００１）。综合疗效显效率替硝唑２组（８４．４％）和甲硝唑组（８４．６％）明显高于替硝唑１组（３７．５％，Ｐ＜０．００１）。而药物不良反应发生率替硝唑２组（３２．４％）和甲硝唑组（１８．４％）较替硝唑１组（５２．９％）呈递减趋势，且程度较轻。停药一周后，替硝唑组和甲硝唑组多数患者（分别为８７．５％和９２．９％）龈下菌斑中螺旋体比例明显回升（Ｐ＜０．０１）。本研究结论为：替硝唑治疗牙周炎宜每日２次给药，并应作为局部治疗的辅助手段
In order to observe the efficacy and adverse drug reaction of tinidazole in treating periodontitis, the dosage regimen of tinidazole Phase Ⅲ was 1.0g · d-1, qd. The first day doubled, the total amount of 4.0g per treatment periodontitis, the results showed significant effect, but the incidence of adverse drug reactions higher. In this study, tinidazole daily dose of sub-sub-program for the treatment of periodontitis in 36 cases (tinidazole two groups), metronidazole treatment of periodontitis in 39 cases (metronidazole group) and phase III clinical trial Dayton Dose regimen group of 38 cases (tinidazole group 1) comparison. The results showed that after taking the three groups of patients except plaque index, the clinical index of each period were significantly lower (P <0.001). The effective rate of tinidazole in group 2 (84.4%) and metronidazole group (84.6%) was significantly higher than that in tinidazole group 1 (37.5%, P <0.001). The incidence of adverse drug reactions in tinidazole group 2 (32.4%) and metronidazole group (18.4%) compared with tinidazole group 1 (52.9%) showed a decreasing trend, and to a lesser extent. After a week of withdrawal, the proportion of spirochaetes in subgingival plaque was significantly increased in most patients (87.5% and 92.9%, respectively) in the tinidazole and metronidazole groups (P <0.01). The conclusion of this study is that tinidazole should be administered twice daily to periodontitis and should be used as an adjunct to local treatment